Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity labeling

Journal of Medicinal Chemistry

Volumn 50, Issue 16, 2007, Pages 3757-3764

  Palmer, Brian D ^a   Henare, Kimiora ^a   Woon, See Tarn ^a   Sutherland, Rachel ^a   Reddy, Charu ^a   Wang, Liang Chuan S ^a   Kieda, Claudine ^b   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZIDO 6 METHYLXANTHENONE 4 ACETIC ACID; 5 AZIDOXANTHENONE 4 ACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; 6 AZIDO 5 METHYLXANTHENONE 4 ACETIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON HEMORRHAGE; COLON TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; MOUSE; NONHUMAN; PHOTOAFFINITY LABELING; PHOTOREACTIVITY; SPLEEN CELL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; AZIDES; CELLS, CULTURED; COLONIC NEOPLASMS; HEMORRHAGE; MICE; MICE, INBRED C57BL; NECROSIS; NF-KAPPA B; PHOTOAFFINITY LABELS; PROTEIN BINDING; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; XANTHONES;

EID: 34548090017     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0702175     Document Type: Article

References (45)

1. Lippert, J. W., 3rd. Vascular disrupting agents. Bioorg. Med. Chem. 2007, 15, 605-615.
2. Gaya, A. M.; Rustin, G. J. S. Vascular disrupting agents: a new class of drug in cancer therapy. Clin. Oncol. 2005, 17, 277-290.
3. Herbst, R. S.; Johnson, D. H.; Mininberg, E.; Carbone, D. P.; Henderson, T.; Kim, E. S.; Blumenschein, G., Jr.; Lee, J. J.; Liu, D. D.; Truong, M. T.; et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 2544-2555.
4. Sandler, A.; Gray, R.; Perry, M. C.; Brahmer, J.; Schiller, J. H.; Dowlati, A.; Lilenbaum, R.; Johnson, D. H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 355, 2542-2550.
5. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5, 423-435.
6. Attard, G.; Greystoke, A.; Kaye, S.; De Bono, J. Update on tubulin-binding agents. Pathol. Biol. 2006, 54, 72-84.
7. Pellegrini, F.; Budman, D. R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. 2005, 23, 264-273.
8. Zwi, L. J.; Baguley, B. C.; Gavin, J. B.; Wilson, W. R. The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethylxanthenone acetic acid on the colon 38 mouse tumor. Pathology 1994, 26, 161-169.
9. Lash, C. J.; Li, A. E.; Rutland, M.; Baguley, B. C.; Zwi, L. J.; Wilson, W. R. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer 1998, 78, 439-445.
10. Ching, L. M.; Cao, Z.; Kieda, C.; Zwain, S.; Jameson, M. B.; Baguley, B. C. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 2002, 86, 1937-1942.
11. Ching, L. M.; Zwain, S.; Baguley, B. C. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br. J. Cancer 2004, 90, 906-910.
12. Baguley, B. C.; Zhuang, L.; Kestell, P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol. Res. 1997, 9, 55-60.
13. Thomsen, L. L.; Baguley, B. C.; Wilson, W. R. Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 1992, 31, 151-155.
14. Philpott, M.; Baguley, B. C.; Ching, L. M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 1995, 36, 143-148.
15. Cao, Z.; Baguley, B. C.; Ching, L. M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Res. 2001, 61, 1517-1521.
16. Perera, P. Y.; Barber, S. A.; Ching, L. M.; Vogel, S. N. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J. Immunol. 1994, 153, 4684-4693.
17. Wang, L.-C. S.; Woon, S.-T.; Baguley, B. C.; Ching, L.-M. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Oncol. Res. 2006, 16, 1-14.
18. Woon, S-T; Hung, S. S.-C; Wu, D. C. F.; Schooltink, M. A.; Rachel Sutherland, R.; Baguley, B. C.; Chen, Q.; Chamley, L. W.; Ching, L.-M. NF-κB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA. Anticancer Res., in press.
19. Safa, A. R. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 7187-7191.
20. Rao, S.; Krauss, N.; Heerding, J.; Swindell, C.; Ringel, I.; Orr, G. A.; Horwitz, S. B. 3′-(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J. Biol. Chem. 1994, 269, 3132-3134.
21. Rao, S.; Orr, G. A.; Chaudhary, A. G.; Kingston, D. G. I.; Horwitz, S. B. Characterization of the Taxol binding site on the microtubule. J. Biol. Chem. 1995, 270, 20235-20238.
22. Rao, S.; He, L.; Chakravarty, S.; Ojima, I.; Orr, G. A.; Horwitz, S. B. Characterization of the Taxol binding site on the microtubule. Identification of Arg282 in beta-tubulin as the site of photoincorporation of a 7-benzophenone analog of Taxol. J. Biol. Chem. 1999, 274, 37990-37994.
23. Turk, B. E.; Jiang, H.; Liu, J. O. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7552-7556.
24. Woon, S.-T.; Baguley, B. C.; Palmer, B. D.; Fraser, J. D.; Ching, L.-M. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines. Oncol. Res. 2002, 13, 95-101.
25. (a) Bayley, H. Photogenerated Reagents in Biochemistry and Molecular Biology. In Laboratory Techniques in Biochemistry and Molecular Biology; Elsevier: Amsterdam, 1983; Vol. 12.
26. (b) Knowles, G. Photogenerated reagents for biological receptor-site labeling. Acc. Chem. Res. 1972, 5, 155-160.
27. (c) Sinz, A. Isotope-labeled photoaffinity reagents and mass spectrometry to identify protein-ligand interactions. Angew. Chem., Int. Ed. 2007, 46, 660-662.
28. Brunner, J. New photolabeling and crosslinking methods. Annu. Rev. Biochem. 1993, 62, 483-514.
29. Rewcastle, G. W.; Atwell, G. J.; Li, Z. A.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 1991, 34, 217-222.
30. Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Relationships between structure and in vivo colon 38 activity for 5-substituted 9-oxoxanthene-4-acetic acids. J. Med. Chem. 1990, 33, 1375-1379.
31. Rewcastle, G. W.; Sutherland, H. S.; Weir, C. A.; Blackburn, A. G.; Denny, W. A. An improved synthesis of isonitrosoacetanilides. Tetrahedron Lett. 2005, 46, 8719-8721.
32. Baguley, B. C.; Calveley, S. B.; Crowe, K. K.; Fray, L. M.; O'Rourke, S. A.; Smith, G. P. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur. J. Cancer Clin. Oncol. 1989, 25, 263-269.
33. Laws, A. L.; Matthew, A. M.; Double, J. A.; Bibby, M. C. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 1995, 71, 1204-1209.
34. Ching, L. M.; Goldsmith, D.; Joseph, W. R.; Korner, H.; Sedgwick, J. D.; Baguley, B. C. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid in TNF knockout mice. Cancer Res. 1999, 59, 3304-3307.
35. Ching, L. M.; Young, H. A.; Eberly, K.; Yu, C. R. Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Biochem. Pharmacol. 1999, 58, 1173-1181.
36. Woon, S. T.; Zwain, S.; Schooltink, M. A.; Newth, A. L.; Baguley, B. C.; Ching, L. M. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Eur. J. Cancer 2003, 39, 1176-1183.
37. Wang, L. C.; Reddy, C. B.; Baguley, B. C.; Kestell, P.; Sutherland, R.; Ching, L. M. Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem. Pharmacol. 2004, 67, 937-945.
38. Ching, L. M.; Finlay, G. J.; Joseph, W. R.; Baguley, B. C. In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid. Eur. J. Cancer 1991, 27, 1684-1689.
39. Woon, S.-T.; Reddy, C. B.; Drummond, C. J.; Schooltink, M. A.; Baguley, B. C.; Kieda, C.; Ching, L.-M. A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines. Oncol. Res. 2005, 15, 351-364.
40. Ching, L. M.; Joseph, W. R.; Zhuang, L.; Atwell, G. J.; Rewcastle, G. W.; Denny, W. A.; Baguley, B. C. Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity. Eur. J. Cancer 1991, 27, 79-83.
41. SibTech, Inc. http://www.sibtech.com.
42. Bizouarne, N.; Mitterrand, M.; Monsigny, M.; Kieda, C. Characterization of membrane sugar-specific receptors in cultured high endothelial cells from mouse peripheral lymph nodes. Biol. Cell 1993, 79, 27-35.
43. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
44. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
45. Sen, R.; Baltimore, D. Inducibility of [kappa] immunoglobulin enhancer-binding protein NF-[kappa]B by a posttranslational mechanism. Cell 1986, 47, 921-928.